Compare Humana Inc (HUM) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs MasTec Inc — how do they compare? Humana Inc trades at $404.61 (market cap $47.81B), while MasTec Inc trades at $349.06 (market cap $26.60B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays a 0.89% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| HUM | MTZ | |
|---|---|---|
Market Cap | $47.81B | $26.60B |
Sector | Health | Technology |
52-Week High | $409.42 | $437.51 |
52-Week Low | $163.67 | $172.51 |
Enterprise Value | $56.85B | $29.34B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
MasTec (MTZ) trades at $336.61, up 2.13% with strong analyst support (88.9% buy ratings) and a consensus price target of $497.45. The stock shows a bearish technical signal despite recent earnings beats, with Q1 2026 EPS of $1.39 surpassing expectations. The company's $1.65 billion acquisition of Superior Group positions it to capitalize on AI-driven data center infrastructure demand, supported by a record $20.3 billion backlog. Valuation metrics include a P/E of 57.72 and ROE of 14.53%, indicating premium pricing but solid profitability.
Outlook remains positive due to infrastructure spending tailwinds and strategic acquisitions, though high valuation and integration risks from the Superior deal warrant caution. Revenue growth is projected to rise from $14.30 billion in 2025 to $15.30 billion in 2026, with net income margin improving to 2.94%. Key risks include execution challenges and macroeconomic sensitivity, but institutional bullishness suggests upside potential if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
